LiMM Therapeutics

📍 Paris, France🗓 Founded 2018👥 6 employees💰 Last funded Jul 2020
Biotechnology Research🌐 limmtx.com
Website LinkedIn
LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. By decoding the language of the neuroimmune cross-talk, we are developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes - to preserve health and treat inflammatory, infectious and metabolic diseases. We are bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Portugal
1
Switzerland
1
Frequently asked questions
Who invested in LiMM Therapeutics?
LiMM Therapeutics has 2 investors on record on gritt.io, including 2 early-stage backers.
When did LiMM Therapeutics last raise funding?
The most recent investment in LiMM Therapeutics recorded on gritt.io was in July 2020.
When was LiMM Therapeutics founded?
LiMM Therapeutics was founded in 2018.
What industry is LiMM Therapeutics in?
LiMM Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is LiMM Therapeutics based?
LiMM Therapeutics is headquartered in Paris, France.